Article

House Call: Treating IBD Patients During COVID-19 Pandemic

Author(s):

David T. Rubin, MD, discusses some of the reccomendations for treating patients with IBD during the pandemic.

The immunosuppressants used to treat patients with inflammatory bowel disease (IBD) can be particularly concerning as many are worried about the coronavirus disease 2019 (COVID-19) attacking immunocompromised individuals.

Recently, the American Gastroenterology Association (AGA) released a set of new recommendations for IBD patients in managing the disease while limiting the risk of negative outcomes should they contract COVID-19.

The new guidance suggest patients with IBD should continue IBD therapies, including all scheduled infusions and patients with IBD who develop COVID-19 should to stop medications such as thiopurines, methotrexate, and tofacitinib, as well as biological therapies including anti-TNF, ustekinumab, and vedolizumab until their symptoms subside.

However, a large portion of patients with COVID-19 become asymptomatic and do not always know whether or not they have the virus.

In an interview with HCPLive® David T. Rubin, MD, University of Chicago Medicine Inflammatory Bowel Disease Center, explained how some of the asymptomatic patients should proceed and what gastroenterology patients in general should be cognizant of during the pandemic.

Related Videos
Age, Race, Ethnicity Disparities Hinder Celiac Disease Screening, with Debra Silberg, MD, PhD
Lauren Collen, MD: Advanced Combination Therapy May Be Effective Option for Pediatric Refractory IBD
Lauren Collen, MD: Some Fragrances May be More Prevalent in Exposomes of Children with Crohn’s Disease
Impact of Long Hospital Stays on Pediatric Gastroparesis Management with Christian Sadaka, MD
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Braden Kuo, MD | Credit: Mass Gen
Satish Rao, MD, PhD | Credit: ACG
Anthony Kerbage, MD | Credit: ResearchGate
Mohammad Abuassi, MD | Credit: ACG
© 2024 MJH Life Sciences

All rights reserved.